Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls

The possible mechanism of increased urinary C‐peptide due to neprilysin inhibitors is investigated. Neprilysin inhibition blocks degradation of natriuretic peptides, and elicits a natriuretic and antihypertensive effect. Neprilysin inhibition might similarly block degradation of C‐peptides in the ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Tomoko, Murakami, Takaaki, Yabe, Daisuke, Harada, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445196/
https://www.ncbi.nlm.nih.gov/pubmed/37357546
http://dx.doi.org/10.1111/jdi.14044
_version_ 1785094125849149440
author Kato, Tomoko
Murakami, Takaaki
Yabe, Daisuke
Harada, Norio
author_facet Kato, Tomoko
Murakami, Takaaki
Yabe, Daisuke
Harada, Norio
author_sort Kato, Tomoko
collection PubMed
description The possible mechanism of increased urinary C‐peptide due to neprilysin inhibitors is investigated. Neprilysin inhibition blocks degradation of natriuretic peptides, and elicits a natriuretic and antihypertensive effect. Neprilysin inhibition might similarly block degradation of C‐peptides in the kidney and thus increase the urinary C‐peptide level.[Image: see text]
format Online
Article
Text
id pubmed-10445196
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104451962023-08-24 Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls Kato, Tomoko Murakami, Takaaki Yabe, Daisuke Harada, Norio J Diabetes Investig Commentary The possible mechanism of increased urinary C‐peptide due to neprilysin inhibitors is investigated. Neprilysin inhibition blocks degradation of natriuretic peptides, and elicits a natriuretic and antihypertensive effect. Neprilysin inhibition might similarly block degradation of C‐peptides in the kidney and thus increase the urinary C‐peptide level.[Image: see text] John Wiley and Sons Inc. 2023-06-25 /pmc/articles/PMC10445196/ /pubmed/37357546 http://dx.doi.org/10.1111/jdi.14044 Text en © 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentary
Kato, Tomoko
Murakami, Takaaki
Yabe, Daisuke
Harada, Norio
Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
title Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
title_full Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
title_fullStr Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
title_full_unstemmed Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
title_short Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
title_sort impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: potential benefits and pitfalls
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445196/
https://www.ncbi.nlm.nih.gov/pubmed/37357546
http://dx.doi.org/10.1111/jdi.14044
work_keys_str_mv AT katotomoko impactoftheangiotensinreceptorneprilysininhibitorinclinicaldiabetesmanagementpotentialbenefitsandpitfalls
AT murakamitakaaki impactoftheangiotensinreceptorneprilysininhibitorinclinicaldiabetesmanagementpotentialbenefitsandpitfalls
AT yabedaisuke impactoftheangiotensinreceptorneprilysininhibitorinclinicaldiabetesmanagementpotentialbenefitsandpitfalls
AT haradanorio impactoftheangiotensinreceptorneprilysininhibitorinclinicaldiabetesmanagementpotentialbenefitsandpitfalls

Ejemplares similares